19 September 2022: Clinical Research
Circulating Methylated DNA Analyses to Predict Recurrence Risk and Adjuvant Chemotherapy Benefit in Stage II to III Colorectal Cancer
Zhen Yuan 12ABCEF* , Shuyuan Wang 12ABCDEF* , Kemin Ni 12ACDF* , Yixiang Zhan 12ACDF* , Hong Ma 1BDF , Xinyu Liu 13ABC , Ran Xin 2ABC , Xingyu Zhou 2BC , Zhaoce Liu 12BC , Xuanzhu Zhao 14BC , Xin Yin 2BC , Hangyu Ping 2BC , Yaohong Liu 2BC , Wanting Wang 4BC , Suying Yan 4BC , Qiurong Han 4BC , Wei Cui 5CD , Xipeng Zhang 167ADF , Qinghuai Zhang 167ABCD* , Chunze Zhang 167ABCDEFG*DOI: 10.12659/MSM.937757
Med Sci Monit 2022; 28:e937757
Supplementary Table 2 Relationship between postoperative mSETP9, CEA, CA19-9, and CA242 levels and recurrence status.
| No recurrence | Recurrence | |
|---|---|---|
| Postoperative CEA elevated | 7/34 (20.6) | 5/19 (26.3) |
| Postoperative CEA not elevated | 27/34 (79.4) | 14/19 (73.7) |
| Postoperative CA19-9 elevated | 1/32 (3.1) | 4/19 (21.1) |
| Postoperative CA19-9 not elevated | 31/32 (96.9) | 15/19 (78.9) |
| Postoperative CA242 elevated | 2/25 (8) | 4/18 (22.2) |
| Postoperative CA242 not elevated | 23/25 (90.2) | 14/18 (77.8) |
| Postoperative CEA elevated | 27/230 (11.7) | 1/13 (7.7) |
| Postoperative CEA not elevated | 203/230 (88.3) | 12/13 (92.3) |
| Postoperative CA19-9 elevated | 15/220 (6.8) | 0/13 (0.0) |
| Postoperative CA19-9 not elevated | 205/220 (93.2) | 13/13 (100.0) |
| Postoperative CA242 elevated | 20/168 (11.9) | 1/12 (8.3) |
| Postoperative CA242 not elevated | 148/168 (88.1) | 11/12 (91.7) |
| mSEPT9 – methylated setpin9. | ||